SmithKline Phase IV commitments include Nicorette study on use by adolescents.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE's PHASE IV COMMITMENTS INCLUDE NICORETTE STUDY ON ADOLESCENT USE of the smoking- cessation aid. In a Feb. 12 letter, FDA reminded SmithKline Beecham of its post-marketing commitment to "conduct an appropriate study of the safety and effectiveness" of Nicorette gum use by adolescents.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning